Novo Nordisk and Eli Lilly report GLP-1 drugs slow aging clock readings
Novo Nordisk tested blood from over 10,000 trial participants using proteomic clocks and found signs that its weight-loss drug slowed biological aging, including up to a 4-year shift in a clock measuring heart protein age. Eli Lilly ran a smaller study on tirzepatide using epigenetic clocks that track DNA changes, and also found molecular aging appeared to slow in patients taking the drug compared to placebo.